GlassScriptPhysician profile
Dawn D Best
NPI 1003049925
$1,475.62
in general payments reported to CMS, 2019-2025
19 companies · $493 in 2025
The $493 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $270 · 2022: $247 · 2023: $218 · 2024: $248 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $914 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $913.86 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $632.54 | 2021-2025 | |
| Exact Sciences Corporation | $150.62 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $133.41 | 2022-2025 | Zepbound, Mounjaro |
| Novo Nordisk INC | $116.83 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $78.89 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $62.30 | 2022-2025 | Farxiga |
| Amgen INC. | $47.84 | 2021-2024 | Prolia, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $45.77 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $44.30 | 2024 | |
| Glaxosmithkline, LLC. | $21.05 | 2024 | Trelegy Ellipta, Arexvy |
| Vanda Pharmaceuticals INC. | $19.87 | 2025 | Fanapt |
| Mylan Specialty L.P. | $18.08 | 2024 | Yupelri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.89 | 2025 | Caplyta |
| Shield Therapeutics INC | $15.96 | 2024 | |
| Gilead Sciences, INC. | $15.30 | 2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $14.86 | 2021 | |
| Eisai INC. | $14.79 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $14.10 | 2021 | |
| Ironshore Pharmaceuticals INC. | $12.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn Best listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.